270 related articles for article (PubMed ID: 35990639)
21. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Passamonti F; Romano A; Salvini M; Merli F; Porta MGD; Bruna R; Coviello E; Romano I; Cairoli R; Lemoli R; Farina F; Venditti A; Busca A; Ladetto M; Massaia M; Pinto A; Arcaini L; Tafuri A; Marchesi F; Fracchiolla N; Bocchia M; Armiento D; Candoni A; Krampera M; Luppi M; Cardinali V; Galimberti S; Cattaneo C; La Barbera EO; Mina R; Lanza F; Visani G; Musto P; Petrucci L; Zaja F; Grossi PA; Bertù L; Pagano L; Corradini P;
Br J Haematol; 2021 Nov; 195(3):371-377. PubMed ID: 34272724
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
24. [Longitudinal Monitoring of Seroconversion Status in SARS-CoV-2 RT-PCR Positive Healthcare Workers].
Ersoy L; Tezcan Ülger S; Gülbudak H; Yaşar N; Yapıcı G; Aslan G
Mikrobiyol Bul; 2022 Jan; 56(1):114-123. PubMed ID: 35088965
[TBL] [Abstract][Full Text] [Related]
25. Dynamic and features of SARS-CoV-2 infection in Gabon.
Mveang Nzoghe A; Padzys GS; Maloupazoa Siawaya AC; Kandet Yattara M; Leboueny M; Avome Houechenou RM; Bongho EC; Mba-Mezeme C; Mvoundza Ndjindji O; Biteghe-Bi-Essone JC; Boulende A; Essone PN; Ndong Sima CAA; Minkobame U; Zang Eyi C; Ndeboko B; Voloc A; Meye JF; Ategbo S; Djoba Siawaya JF
Sci Rep; 2021 May; 11(1):9672. PubMed ID: 33958601
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark.
Johannesen CK; Rezahosseini O; Gybel-Brask M; Kristensen JH; Hasselbalch RB; Pries-Heje MM; Nielsen PB; Knudsen AD; Fogh K; Norsk JB; Andersen O; Jensen CAJ; Torp-Pedersen C; Rungby J; Ditlev SB; Hageman I; Møgelvang R; Dessau RB; Sørensen E; Harritshøj LH; Folke F; Sten C; Møller MEE; Engsig FN; Ullum H; Jørgensen CS; Ostrowski SR; Bundgaard H; Iversen KK; Fischer TK; Nielsen SD
Microbiol Spectr; 2021 Oct; 9(2):e0090421. PubMed ID: 34668738
[TBL] [Abstract][Full Text] [Related]
27. High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients.
Ruan W; Nguyen H; Wyatt A; Ihekweazu F; Vartabedian BS; Karam L; Walsh S; Kellermayer R
J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):363-366. PubMed ID: 34173793
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Antibody Response among Women Infected during Pregnancy.
Buckley A; Mills A; Paul K; Raymond S; Mendu DR; DeBolt C; Rosenberg M; Wajnberg A; Szeto L; Cochrane E; Vieira L; Berkin J; Ferrera L; Stone J; Bianco A
Am J Perinatol; 2022 May; 39(7):707-713. PubMed ID: 34768307
[TBL] [Abstract][Full Text] [Related]
29. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
30. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs.
Van Elslande J; Decru B; Jonckheere S; Van Wijngaerden E; Houben E; Vandecandelaere P; Indevuyst C; Depypere M; Desmet S; André E; Van Ranst M; Lagrou K; Vermeersch P
Clin Microbiol Infect; 2020 Nov; 26(11):1557.e1-1557.e7. PubMed ID: 32745595
[TBL] [Abstract][Full Text] [Related]
31. Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients.
Chen Y; Li P; Ding Y; Liu M; Liu L; Yi B; Wu T; Dong H; Lao X; Ding K; Wang H; Zhang D; Tan X; Wang Z; Xu G; Cao G
J Infect Public Health; 2021 Jul; 14(7):845-851. PubMed ID: 34118734
[TBL] [Abstract][Full Text] [Related]
32. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
34. Do the Kinetics of Antibody Responses Predict Clinical Outcome in Hospitalized Patients With Moderate-to-Severe COVID-19?
Pavlidis G; Kampolis CF; Perlepe G; Pagonis A; Maniotis C; Koullias E; Kranidioti H; Kyritsis A; Pavlou E; Sinis S; Pirounaki M; Vassilopoulos D; Gourgoulianis K; Pantazopoulos I
In Vivo; 2022; 36(4):1944-1948. PubMed ID: 35738610
[TBL] [Abstract][Full Text] [Related]
35. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.
Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
J Appl Lab Med; 2020 Sep; 5(5):908-920. PubMed ID: 32428207
[TBL] [Abstract][Full Text] [Related]
37. Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay.
Alshami A; Al Attas R; Anan H; Al Maghrabi A; Ghandorah S; Mohammed A; Alhalimi A; Al-Jishi J; Alqahtani H
Front Microbiol; 2021; 12():770727. PubMed ID: 34925278
[No Abstract] [Full Text] [Related]
38. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
39. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.
Re D; Barrière J; Chamorey E; Delforge M; Gastaud L; Petit E; Chaminade A; Verrière B; Peyrade F
Leuk Lymphoma; 2021 Dec; 62(13):3308-3310. PubMed ID: 34308748
[No Abstract] [Full Text] [Related]
40. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
